Many patients with hormone receptor-positive breast cancer are treated with an aromatase inhibitor (AI). Around half of these patients experience joint and muscle pain, stiffness, tiredness and weight gain as side effects. These complaints often lead to patients doing less exercise, thus impairing their quality of life.

In trial SAKK 95/17, developed and led by MSc Nicolette Hoefnagels and Dr. Friedemann Honecker, we are investigating whether an exercise regimen at the start of the AI treatment can improve the tolerability of the treatment, alleviate the side effects, and increase the patients’ quality of life.

Further information on the trial can be found here.